MSFT   211.82 (-0.87%)
AMZN   3,229.32 (+0.92%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.75%)
BABA   255.72 (-2.03%)
MU   50.52 (-0.36%)
GE   6.78 (+1.35%)
TSLA   1,569.94 (+1.64%)
AMD   55.76 (-0.21%)
T   29.88 (-0.83%)
ACB   12.34 (+2.66%)
F   6.15 (+0.82%)
NFLX   551.66 (+0.53%)
BA   180.32 (+1.05%)
MSFT   211.82 (-0.87%)
AMZN   3,229.32 (+0.92%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.75%)
BABA   255.72 (-2.03%)
MU   50.52 (-0.36%)
GE   6.78 (+1.35%)
TSLA   1,569.94 (+1.64%)
AMD   55.76 (-0.21%)
T   29.88 (-0.83%)
ACB   12.34 (+2.66%)
F   6.15 (+0.82%)
NFLX   551.66 (+0.53%)
BA   180.32 (+1.05%)
MSFT   211.82 (-0.87%)
AMZN   3,229.32 (+0.92%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.75%)
BABA   255.72 (-2.03%)
MU   50.52 (-0.36%)
GE   6.78 (+1.35%)
TSLA   1,569.94 (+1.64%)
AMD   55.76 (-0.21%)
T   29.88 (-0.83%)
ACB   12.34 (+2.66%)
F   6.15 (+0.82%)
NFLX   551.66 (+0.53%)
BA   180.32 (+1.05%)
MSFT   211.82 (-0.87%)
AMZN   3,229.32 (+0.92%)
NVDA   415.41 (-0.90%)
CGC   17.90 (+2.75%)
BABA   255.72 (-2.03%)
MU   50.52 (-0.36%)
GE   6.78 (+1.35%)
TSLA   1,569.94 (+1.64%)
AMD   55.76 (-0.21%)
T   29.88 (-0.83%)
ACB   12.34 (+2.66%)
F   6.15 (+0.82%)
NFLX   551.66 (+0.53%)
BA   180.32 (+1.05%)
Log in

NYSE:NGVTIngevity Stock Price, Forecast & News

$54.98
+1.79 (+3.37 %)
(As of 07/13/2020 02:33 PM ET)
Add
Compare
Today's Range
$53.52
Now: $54.98
$55.53
50-Day Range
$47.31
MA: $52.63
$57.89
52-Week Range
$24.92
Now: $54.98
$104.76
Volume8,115 shs
Average Volume352,495 shs
Market Capitalization$2.27 billion
P/E Ratio11.27
Dividend YieldN/A
Beta2.42
Ingevity Corporation manufactures and sells specialty chemicals and carbon materials in the United States and internationally. The company operates through two segments, Performance Materials and Performance Chemicals. The Performance Materials segment engineers, manufactures, and sells hardwood-based and chemically activated carbon products primarily for use in gasoline vapor emission control systems in cars, trucks, motorcycles, and boats. This segment also produces other activated carbon products for use in various applications, including food, water, beverage, and chemical purification. The Performance Chemicals segment develops, manufactures, and sells a range of specialty chemicals derived from co-products of the Kraft pulping process and caprolactone. This segment's products are used in various applications comprising pavement preservation, pavement adhesion promotion and warm mix paving, oil well service additives, oil production and downstream application chemicals, printing inks, adhesives, agrochemicals, lubricants and industrial intermediates, coatings resins, elastomers, adhesives, and bio-plastics. Ingevity Corporation was incorporated in 2015 and is headquartered in North Charleston, South Carolina.
Read More
Ingevity logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.88 out of 5 stars


Industry, Sector and Symbol

Industry Chemicals & allied products
Sub-IndustryN/A
Previous SymbolNASDAQ:NGVT
CUSIPN/A
Phone843-740-2300

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.29 billion
Cash Flow$7.24 per share
Book Value$12.69 per share

Profitability

Net Income$183.70 million

Miscellaneous

Employees1,850
Market Cap$2.27 billion
Next Earnings Date7/29/2020 (Confirmed)
OptionableOptionable

Receive NGVT News and Ratings via Email

Sign-up to receive the latest news and ratings for NGVT and its competitors with MarketBeat's FREE daily newsletter.

Ingevity (NYSE:NGVT) Frequently Asked Questions

How has Ingevity's stock been impacted by COVID-19 (Coronavirus)?

Ingevity's stock was trading at $38.80 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NGVT stock has increased by 41.7% and is now trading at $54.98. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ingevity?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ingevity in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ingevity.

When is Ingevity's next earnings date?

Ingevity is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Ingevity.

How can I listen to Ingevity's earnings call?

Ingevity will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Ingevity's earnings last quarter?

Ingevity Corp (NYSE:NGVT) announced its quarterly earnings results on Wednesday, April, 29th. The company reported $1.12 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.84 by $0.28. The company had revenue of $288.20 million for the quarter, compared to analysts' expectations of $263.61 million. Ingevity had a return on equity of 45.48% and a net margin of 15.82%. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. During the same period last year, the firm earned $0.99 EPS. View Ingevity's earnings history.

What guidance has Ingevity issued on next quarter's earnings?

Ingevity issued an update on its second quarter 2020 After-Hours earnings guidance on Wednesday, April, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $246.96-264.6 million, compared to the consensus revenue estimate of $325.64 million.

What price target have analysts set for NGVT?

7 Wall Street analysts have issued 1 year price targets for Ingevity's shares. Their forecasts range from $42.00 to $107.00. On average, they anticipate Ingevity's share price to reach $73.14 in the next twelve months. This suggests a possible upside of 33.0% from the stock's current price. View analysts' price targets for Ingevity.

Has Ingevity been receiving favorable news coverage?

News headlines about NGVT stock have trended very negative on Monday, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Ingevity earned a news impact score of -3.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news about Ingevity.

Are investors shorting Ingevity?

Ingevity saw a decrease in short interest in the month of June. As of June 30th, there was short interest totaling 1,400,000 shares, a decrease of 11.4% from the June 15th total of 1,580,000 shares. Based on an average daily volume of 516,700 shares, the days-to-cover ratio is currently 2.7 days. Approximately 3.4% of the shares of the company are short sold. View Ingevity's Current Options Chain.

Who are some of Ingevity's key competitors?

What other stocks do shareholders of Ingevity own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ingevity investors own include AbbVie (ABBV), Pfizer (PFE), Verizon Communications (VZ), Costco Wholesale (COST), Dominion Energy (D), General Electric (GE), Quaker Chemical (KWR), Boeing (BA), Alibaba Group (BABA) and Walt Disney (DIS).

Who are Ingevity's key executives?

Ingevity's management team includes the following people:
  • Mr. D. Michael Wilson, Pres, CEO & Director (Age 56)
  • Mr. John C. Fortson, Exec. VP, CFO & Treasurer (Age 52)
  • Ms. Katherine Pryor Burgeson, Exec. VP, Gen. Counsel & Sec. (Age 61)
  • Mr. Stuart Edward Woodcock Jr., Exec. VP & Pres of Performance Materials (Age 53)
  • Mr. Michael P. Smith, Exec. VP and Pres of Performance Chemicals, Strategy & Bus. Devel. (Age 58)

What is Ingevity's stock symbol?

Ingevity trades on the New York Stock Exchange (NYSE) under the ticker symbol "NGVT."

Who are Ingevity's major shareholders?

Ingevity's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.05%). Company insiders that own Ingevity stock include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Katherine Pryor Burgeson, Michael P Smith, Phillip John Platt and Richard B Kelson. View institutional ownership trends for Ingevity.

Which major investors are buying Ingevity stock?

NGVT stock was bought by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have bought Ingevity stock in the last two years include D Michael Wilson, Diane H Gulyas, Frederick J Lynch, John C Fortson, Michael P Smith, and Richard B Kelson. View insider buying and selling activity for Ingevity.

How do I buy shares of Ingevity?

Shares of NGVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ingevity's stock price today?

One share of NGVT stock can currently be purchased for approximately $54.98.

How big of a company is Ingevity?

Ingevity has a market capitalization of $2.27 billion and generates $1.29 billion in revenue each year. The company earns $183.70 million in net income (profit) each year or $4.93 on an earnings per share basis. Ingevity employs 1,850 workers across the globe.

What is Ingevity's official website?

The official website for Ingevity is www.ingevity.com.

How can I contact Ingevity?

Ingevity's mailing address is 5255 Virginia Avenue, North Charleston SC, 29406. The company can be reached via phone at 843-740-2300 or via email at [email protected]

This page was last updated on 7/13/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.